<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Presentation, diagnosis, and staging of Wilms tumor</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Presentation, diagnosis, and staging of Wilms tumor</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Presentation, diagnosis, and staging of Wilms tumor</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Valeria Smith, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Murali Chintagumpala, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alberto S Pappo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Wilms tumor is the most common renal malignancy in children, with approximately 500 new cases diagnosed in the United States each year [<a href="#rid1">1</a>]. The epidemiology, presentation, diagnosis, and staging of Wilms tumor will be reviewed here. The treatment and outcome of Wilms tumor are discussed separately. (See  <a class="medical medical_review" href="/d/html/6237.html" rel="external">"Treatment and prognosis of Wilms tumor"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>In the United States, the annual incidence of renal tumors is approximately 7 cases per 1 million children younger than 15 years, accounting for 5 percent of all childhood malignancies  (<a class="graphic graphic_table graphicRef99680" href="/d/graphic/99680.html" rel="external">table 1</a>) and approximately 500 new cases per year [<a href="#rid1">1-4</a>]. Wilms tumor is the most common renal malignancy in children &lt;15 years old, accounting for approximately 95 percent of all cases. In the United States, two-thirds of cases of Wilms tumor are diagnosed before five years of age and 95 percent before 10 years of age [<a href="#rid5">5</a>]. In contrast, renal cell carcinoma (RCC) is more common in the 15- to 19-year-old age group [<a href="#rid5">5</a>].</p><p>Most patients have solitary Wilms tumor, 5 to 7 percent have bilateral kidney involvement, and 10 percent have multifocal loci within a single kidney [<a href="#rid6">6</a>]. In patients with unilateral involvement, the median age at diagnosis is 43 months in girls and 37 months in boys [<a href="#rid7">7</a>]. Children with bilateral disease are diagnosed at an earlier age (median age 31 months for girls and 24 months for boys) [<a href="#rid7">7</a>]. Patients with associated congenital anomalies, such as aniridia or genitourinary abnormalities, are also diagnosed at an earlier age [<a href="#rid7">7</a>].</p><p>The risk of developing Wilms tumor varies among ethnic groups, with a greater risk in African Americans and a lower risk in the Asian population [<a href="#rid3">3,7-9</a>]. Epigenetic differences may contribute to the lower rate of disease in Asian children, as demonstrated by a study that reported infrequent loss of insulin-like growth factor 2 (<em>IGF-2</em>) imprinting in tumors from Asian patients [<a href="#rid10">10</a>]. (See <a class="local">'Genetics'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">ASSOCIATED CONGENITAL SYNDROMES</span><span class="headingEndMark"> — </span>Wilms tumor is primarily a sporadic disease, and only 1 to 2 percent of individuals with Wilms tumor have a relative with the disease [<a href="#rid11">11</a>]. In approximately 10 percent of cases, Wilms tumor occurs as a part of a multiple malformation syndrome, including WAGR, Denys-Drash, and Beckwith-Wiedemann syndrome (BWS) [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H4"><span class="h2">WAGR syndrome</span><span class="headingEndMark"> — </span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fomim.org%2Fentry%2F194072&amp;token=O25AxH2ZrpTPG8o%2BGEGTWHd%2FXekaRRHk%2BF49ZC0Qj7yefhJo5rM7aBAX04CLk2ED&amp;TOPIC_ID=6249" target="_blank">WAGR syndrome</a> refers to the syndrome of <strong>W</strong>ilms tumor, <strong>a</strong>niridia, <strong>g</strong>enitourinary anomalies, and intellectual disability (mental <strong>r</strong>etardation) [<a href="#rid13">13</a>]. In children with WAGR syndrome, the risk of developing Wilms tumor is approximately 50 percent [<a href="#rid12">12,14</a>]. Children with this syndrome have a constitutional chromosomal deletion of the <em>WT1</em> gene located at 11p13. The <em>WT1</em> gene product is a transcription factor involved in both gonadal and renal development. (See <a class="local">'Genetics'</a> below.)</p><p>In a retrospective study of 54 children with WAGR syndrome, the following clinical findings were noted [<a href="#rid15">15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Aniridia – 53 patients</p><p class="bulletIndent1"><span class="glyph">●</span>Genitourinary abnormalities (eg, cryptorchidism, ambiguous genitalia) – 41 patients</p><p class="bulletIndent1"><span class="glyph">●</span>Intellectual disability – 39 patients</p><p class="bulletIndent1"><span class="glyph">●</span>Wilms tumor – 31 patients</p><p class="bulletIndent1"><span class="glyph">●</span>Renal impairment (defined as glomerular filtration rate &lt;80 mL/min) and proteinuria developed in 14 patients</p><p></p><p>In another case series of 64 patients with WAGR syndrome, all patients had tumors with favorable histology [<a href="#rid16">16</a>]. Eleven (7 percent) had bilateral disease. Chronic renal disease developed in approximately one-half of the cohort at a 20-year follow-up, including end-stage kidney disease in four patients who subsequently underwent renal transplantation.</p><p class="headingAnchor" id="H5"><span class="h2">Denys-Drash syndrome</span><span class="headingEndMark"> — </span>The <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fomim.org%2Fentry%2F194080&amp;token=O25AxH2ZrpTPG8o%2BGEGTWA1wjQm5Qn1RYirmzT0yBf5USTLuzG5OCniFYJZ36Upk&amp;TOPIC_ID=6249" target="_blank">Denys-Drash syndrome</a> (also called simply Drash syndrome) is a triad of progressive renal disease, male pseudohermaphroditism, and Wilms tumor. Affected individuals have a germline point mutation in the eighth or ninth exon of the <em>WT1</em> gene, which results in an amino acid substitution, and almost all patients (90 percent) will develop Wilms tumor. (See <a class="local">'Genetics'</a> below.)</p><p>The underlying renal pathology is diffuse mesangial sclerosis, which presents in infancy with proteinuria and progresses to nephrotic syndrome and renal failure. (See  <a class="medical medical_review" href="/d/html/6137.html" rel="external">"Congenital nephrotic syndrome", section on 'Diffuse mesangial sclerosis with Denys-Drash syndrome'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Beckwith-Wiedemann syndrome</span><span class="headingEndMark"> — </span>Patients with <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F130650&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2FU8bDEOj7%2BVX4ijIhuvOLFADHDwBepb25w3PQQ%2B%2FY6Q&amp;TOPIC_ID=6249" target="_blank">BWS</a> have a 5 to 10 percent chance of developing Wilms tumors [<a href="#rid17">17</a>]. This disorder is caused by microduplication mutations in the 11p15.5 region, a site of a cluster of imprinting genes [<a href="#rid18">18</a>]. (See <a class="local">'Genetics'</a> below.)</p><p>The major clinical features of BWS include macrosomia, macroglossia, omphalocele, prominent eyes, ear creases, large kidneys, pancreatic hyperplasia, and hemihypertrophy. (See  <a class="medical medical_review" href="/d/html/13555.html" rel="external">"Beckwith-Wiedemann syndrome"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Other congenital anomalies</span><span class="headingEndMark"> — </span>Patients with other congenital syndromes and isolated congenital anomalies are also at risk for developing Wilms tumors. These include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fomim.org%2Fentry%2F267000&amp;token=O25AxH2ZrpTPG8o%2BGEGTWL2lJgt96Jx0NpIy2p6MB4PauPtemAwDgO2yK8iUgN93&amp;TOPIC_ID=6249" target="_blank">Perlman syndrome</a> – Perlman syndrome is an autosomal recessive overgrowth syndrome due to a germline mutation of the <em>DIS3L2</em> gene [<a href="#rid19">19,20</a>]. It is characterized by fetal gigantism, visceromegaly, unusual face, bilateral renal hamartomas with nephroblastomatosis, and Wilms tumor [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fomim.org%2Fentry%2F117550&amp;token=O25AxH2ZrpTPG8o%2BGEGTWKZ17LJadMm7tjEXsaMCXjH7w%2FNAlIBHwWJKPs8p2oyc&amp;TOPIC_ID=6249" target="_blank">Sotos syndrome</a> – There is a 2 to 3 percent risk of Wilms tumor in children with Sotos syndrome (also referred to as cerebral gigantism). Sotos syndrome is an overgrowth syndrome associated with facial, extremity, and cognitive abnormalities [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/5848.html" rel="external">"The child with tall stature and/or abnormally rapid growth", section on 'Cerebral gigantism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fomim.org%2Fentry%2F312870&amp;token=O25AxH2ZrpTPG8o%2BGEGTWLZ33QcSXaNSFIcdQPtVHmZFFmm6bLUBOesdpnjYzlQ9&amp;TOPIC_ID=6249" target="_blank">Simpson-Golabi-Behmel syndrome</a> – Simpson-Golabi-Behmel syndrome is an X-linked genetic disorder caused by mutations in the gene encoding glypican-3, which maps to chromosome Xq26 [<a href="#rid22">22</a>]. It is characterized with pre- and postnatal overgrowth with organomegaly, a distinctive coarse facial appearance described as a bulldog appearance, congenital heart disease, polydactyly, and a 7.5 percent chance of developing Wilms tumor [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Isolated hemihypertrophy – The estimated risk for developing Wilms tumor in children with isolated hemihypertrophy is 3 to 4 percent [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Isolated genitourinary abnormalities – Boys with Wilms tumor may have cryptorchidism or hypospadias, while 10 percent of girls with Wilms tumor have congenital uterine anomalies [<a href="#rid25">25</a>]. Other kidney abnormalities, such as renal ectopia or duplicated collecting systems, can also be seen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Familial Wilms tumor is rare and is associated with mutations in the <em>BRCA2 </em>or <em>TP53</em> genes (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fomim.org%2Fentry%2F151623&amp;token=O25AxH2ZrpTPG8o%2BGEGTWEoivaVSjZWWGR6K1y0nscB3ElD6tD52%2FsV%2Fud9U8Iw0&amp;TOPIC_ID=6249" target="_blank">Li-Fraumeni syndrome</a>). (See  <a class="medical medical_review" href="/d/html/14255.html" rel="external">"Li-Fraumeni syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Wilms tumor appears to be caused by abnormal renal development, resulting in proliferation of the metanephric blastema without normal tubular and glomerular differentiation. Wilms tumor is thought to arise from foci of persistent metanephric cells referred to as nephrogenic rests or nephroblastomatosis [<a href="#rid26">26</a>]. Nephrogenic rests normally occur in 1 percent of newborn kidneys and regress early in childhood. In contrast, they are present in 35 percent of kidneys with unilateral Wilms tumor and almost 100 percent of kidneys with bilateral disease [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>Wilms tumor has been associated with loss-of-function mutations of a number of tumor suppressor and transcription genes. These include mutations of the <em>WT1</em>, p53, <em>FWT1</em>, and <em>FWT2</em> genes and at the 11p15.5 locus [<a href="#rid28">28</a>]. The role of these gene mutations in the pathogenesis of Wilms tumor remains unknown.</p><p class="bulletIndent1"><span class="glyph">●</span><em>WT1</em> gene – The <em>WT1</em> gene is located on chromosome 11p13. The <em>WT1</em> gene product is expressed in the developing kidney, testis, and ovary. It appears to play a role in the development and differentiation of genitourinary tissues. Mutations of the <em>WT1</em> gene were the first identified genetic abnormalities in children with Wilms tumor and were discovered in karyotypic analysis of children with WAGR syndrome [<a href="#rid29">29</a>]. The 11p13 deletion in WAGR syndrome encompasses several contiguous genes, including the <em>WT1</em> and <em>PAX6</em> (associated with aniridia) genes. In contrast, patients with Denys-Drash syndrome have a point mutation in the eighth or ninth exon of the <em>WT1</em> gene, resulting in their clinical findings. Less than 10 percent of patients with sporadic Wilms tumor have a <em>WT1</em> gene mutation, suggesting that other mechanisms are involved [<a href="#rid30">30</a>]. (See <a class="local">'WAGR syndrome'</a> above and <a class="local">'Denys-Drash syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>11p15.5 – The 11p15.5 locus (also referred to as the <em>WT2 </em>gene locus) contains a cluster of imprinted genes. Mutations at this locus have been identified in a number of syndromes characterized by either growth retardation or overgrowth, including Beckwith-Wiedemann syndrome (BWS) [<a href="#rid12">12,18,31</a>]. Imprinted genes are those that demonstrate selective gene expression based upon parental origin, such that either the paternal- or maternal-inherited gene copy is expressed, but not both. As an example, in patients with BWS, the maternal copy of the Beckwith-Wiedemann gene is silenced during gametogenesis and only the paternal copy is expressed. As a result, offspring with BWS receive a mutation passed from their father and those who inherit a Beckwith-Wiedemann gene mutation from their mother are asymptomatic carriers, who can pass the mutation to their offspring. Patients with BWS and 11p15 gene mutations are at increased risk for Wilms tumor [<a href="#rid12">12,31</a>]. (See  <a class="medical medical_review" href="/d/html/14601.html" rel="external">"Principles of epigenetics"</a> and  <a class="medical medical_review" href="/d/html/2897.html" rel="external">"Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)", section on 'Parent-of-origin effects (imprinting)'</a> and <a class="local">'Beckwith-Wiedemann syndrome'</a> above.)</p><p></p><p class="bulletIndent1">Somatic 11p15 defects have been found in Wilms tumor cells, perilobar nephrogenic rests associated with Wilms tumors, and some normal renal cells surrounding Wilms tumors, suggesting 11p15 mutations may play an early role in nonsyndromic Wilms tumorigenesis [<a href="#rid32">32</a>]. In addition, one study demonstrated germline (constitutional) mutations in genes from this locus in the lymphocytes of 3 percent of nonsyndromic Wilms tumor patients (13 of 437 patients) and in one family with Wilms tumors [<a href="#rid33">33</a>]. No 11p15 defect was detected in the 220 controls. Patients with constitutional 11p15 defects were more likely to have bilateral tumor involvement compared with those without 11p15 mutations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>p53</em> gene – The <em>p53</em> tumor suppressor gene is located on chromosome 17p13.1. It encodes a nuclear protein, which acts as a transcription factor and blocks the progression of the cell cycle late in the G1 phase. <em>p53</em> is the most commonly mutated gene in human cancer and is associated with a variety of malignancies including colorectal cancer, non-small cell lung cancer, osteosarcoma, and Ewing sarcoma. The <em>p53</em> gene mutation is seen infrequently in patients with favorable histology tumors, but it is seen in approximately 75 percent of Wilms tumors with anaplastic histology [<a href="#rid34">34</a>]. In one study, <em>p53</em> mutational status in patients with diffuse anaplasia was associated with increased risk of tumor recurrence and mortality [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Familial <em>WT</em> genes – Familial Wilms tumor accounts for 1 to 2 percent of cases. The mode of inheritance appears to be autosomal dominant with variable penetrance. In these families, there is no association with the <em>WT1</em> gene mutations. Linkages have been demonstrated to the <em>FWT1</em> gene locus at 17q12-21 [<a href="#rid36">36,37</a>], the <em>FWT2</em> gene locus at 19q13.3-q13.4, and the 11p15.5 locus [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other potential gene mutations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A genome-wide association study of 757 patients with Wilms tumor and 1879 controls identified 2p24 and 11q14 as genetic loci related with Wilms tumorigenesis [<a href="#rid39">39</a>]. Additional candidate predisposition loci included 5q14, 22q12, and Xp22.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genes identified as being mutated in Wilms tumor include <em>WTX </em>(classic oncogene) on the X chromosome and B-catenin (<em>CTNNB1</em>), although they occur either singly or in combination in only one-third of tumors [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mutations identified through whole-genome and whole-exome sequencing include those in microRNA processing genes, <em>SIX1</em> and <em>SIX2</em> homeodomain genes, and the <em>MLLT1</em> gene [<a href="#rid40">40,41</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Though the incidence of Wilms tumor is low in <em>DICER1</em> syndrome, it has been reported [<a href="#rid42">42</a>].</p><p></p><p>It remains unknown whether the presence of any of the above genes associated with Wilms tumor affect response to therapy or are predictive of outcome.</p><p>Limited data suggest that patients with <em>WT1</em> germline mutations have a poorer outcome. This was illustrated in one study from the International Society of Pediatric Oncology that demonstrated that patients with <em>WT1</em> germline mutations had an increased risk for bilateral involvement, second tumor events, and poor response to initial chemotherapy [<a href="#rid43">43</a>]. The poor response correlated with stromal predominant tumors with rhabdomyomatous changes. However, further studies are needed before treatment stratification should be considered based upon the presence or absence of a <em>WT1</em> germline mutation [<a href="#rid44">44</a>].</p><p>In addition, patients with 11p15.5 constitutional defects appear to be more likely to have bilateral involvement [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H10"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Most Wilms tumors are solitary lesions. However, 5 to 7 percent of patients have bilateral renal involvement and 10 percent have multifocal loci within a single kidney [<a href="#rid6">6</a>].</p><p>Wilms tumor may include cysts, hemorrhage, or necrosis. The tumor is typically surrounded by a pseudocapsule, which may help distinguish it from other renal tumors (which have an infiltrative border) [<a href="#rid6">6</a>]. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Histologically, the classic favorable histology Wilms tumor is comprised of three cell types  (<a class="graphic graphic_picture graphicRef106078" href="/d/graphic/106078.html" rel="external">picture 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Blastemal cells – Undifferentiated cells</p><p class="bulletIndent1"><span class="glyph">●</span>Stromal cells – Immature spindle cells and heterologous skeletal muscle, cartilage, osteoid, or fat</p><p class="bulletIndent1"><span class="glyph">●</span>Epithelial cells – Glomeruli and tubules</p><p></p><p>Some Wilms tumors contain only one or two cell types. In tumors with only one cell type, it is often difficult to make the diagnosis of Wilms tumor.</p><p>Tumor histology is linked to patient outcome. Anaplasia, defined as the presence of multipolar polypoid mitotic figures and marked nuclear enlargement with hyperchromasia  (<a class="graphic graphic_picture graphicRef106079" href="/d/graphic/106079.html" rel="external">picture 2</a>), is associated with poor outcome [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/d/html/6237.html" rel="external">"Treatment and prognosis of Wilms tumor", section on 'Anaplastic histology'</a>.)</p><p>Blastemal type histology, assessed after preoperative chemotherapy (as performed in protocols of the International Society of Paediatric Oncology [SIOP]), also appears to be associated with poor outcome; however, blastemal content has less prognostic significance when histologic categorization is performed before chemotherapy (as in National Wilms Tumor Study protocols). (See  <a class="medical medical_review" href="/d/html/6237.html" rel="external">"Treatment and prognosis of Wilms tumor", section on 'Blastemal type histology'</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Most children with Wilms tumor present with an abdominal mass or swelling, without other signs or symptoms. Other symptoms can include abdominal pain (30 to 40 percent of patients), hematuria (12 to 25 percent), fever, and hypertension (25 percent) [<a href="#rid6">6,46</a>].</p><p>A subset of patients with subcapsular hemorrhage can present with rapid abdominal enlargement, anemia, hypertension, and, sometimes, fever. Although the lung is the most common metastatic site, children rarely present with respiratory symptoms.</p><p>Physical examination reveals a firm, nontender, smooth mass that is eccentrically located and rarely crosses the midline [<a href="#rid6">6</a>].</p><p>Once a Wilms tumor is suspected, subsequent abdominal examinations should be performed carefully. Vigorous palpation may rupture the renal capsule, resulting in tumor spillage, which increases the tumor stage and the need for more intensive therapy. (See <a class="local">'Staging'</a> below and  <a class="medical medical_review" href="/d/html/6237.html" rel="external">"Treatment and prognosis of Wilms tumor", section on 'Management'</a>.)</p><p>As noted above, Wilms tumor may be associated with congenital anomalies and syndromes. Thus, the examination should include assessment for associated anomalies, such as aniridia, hemihypertrophy, and genitourinary anomalies. (See <a class="local">'Associated congenital syndromes'</a> above.)</p><p>Although Wilms tumor is rarely diagnosed in the neonate [<a href="#rid47">47</a>], there are a few reported cases of prenatal detection of a renal mass with postnatal confirmation of Wilms tumor [<a href="#rid47">47-51</a>]. All of these prenatal cases were unilateral, and none was associated with multiple malformation syndrome or nephrogenic rests. One neonate presented with nonimmune hydrops with rapid growth of the tumor [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H4106510125"><span class="h1">SCREENING</span><span class="headingEndMark"> — </span>Patients with Wilms tumor may also be identified through screening of high-risk patients (eg, children with Beckwith-Wiedemann syndrome [BWS] or WAGR syndrome) [<a href="#rid14">14,52-57</a>]. Surveillance with serial abdominal ultrasonography is recommended, as follows [<a href="#rid14">14,57</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Children with BWS or isolated hemihyperplasia – Every three months until age seven years</p><p class="bulletIndent1"><span class="glyph">●</span>Children with WAGR and <em>WT1</em>-related syndromes – Every three months until age five years</p><p class="bulletIndent1"><span class="glyph">●</span>Siblings of an individual with familial Wilms tumor and offspring of survivors of bilateral Wilms tumor – Every three months until age eight years</p><p></p><p class="headingAnchor" id="H12"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>The definitive diagnosis of Wilms tumor is made by histologic confirmation at the time of either surgical excision or biopsy. Children who are suspected of having Wilms tumor should be referred to a pediatric cancer center for evaluation and diagnosis.</p><p class="headingAnchor" id="H13"><span class="h2">Abdominal imaging</span><span class="headingEndMark"> — </span>Imaging is useful to differentiate Wilms tumor from other causes of abdominal masses. The first goal of imaging is to establish the presence of a renal tumor [<a href="#rid6">6</a>]. Imaging studies also guide management decisions prior to confirmation of a histologic diagnosis, such as surgical approach and need for preoperative chemotherapy. Important information includes confirming the presence and function of the contralateral kidney as well as determining whether there is also tumor in the contralateral kidney, the size and extent of the tumor, and the presence of lung metastases. (See <a class="local">'Chest imaging'</a> below.)</p><p>Abdominal ultrasonography is typically the initial study performed for evaluation of abdominal mass (see  <a class="medical medical_review" href="/d/html/6243.html" rel="external">"Overview of common presenting signs and symptoms of childhood cancer", section on 'Abdominal masses'</a>). Ultrasonography detects hydronephrosis and multicystic kidney disease, which may present as abdominal masses or swelling. In patients with a suspected renal tumor, Doppler ultrasonography can be performed to detect tumor infiltration of the renal vein and inferior vena cava and to assess patency of blood flow. This information can also be clarified with computed tomography (CT).</p><p>Contrast-enhanced CT or magnetic resonance imaging (MRI) is recommended to further evaluate the nature and extent of the mass, including evidence of preoperative rupture or ascites. CT or MRI also may detect small lesions of tumor or nephrogenic rests in the opposite kidney that were not detected by ultrasonography. The Children's Oncology Group (COG) evaluated the diagnostic performance of CT and MRI for local staging of pediatric renal tumors and found that they have similar abilities to detect lymph node metastasis and capsular penetration [<a href="#rid58">58</a>]. MRI detected more contralateral synchronous lesions; however, these were rare. The investigators concluded that either modality can be used for initial locoregional staging of pediatric renal tumors based on institutional expertise, need for anesthesia, risks of radiation exposure, and cost concerns. At the authors' institution, we typically use CT at the time of initial diagnosis; MRI or CT may be used for follow-up imaging depending on the patient's specific circumstances.</p><p>In a separate study, the COG investigated the role of preoperative CT scans in detecting tumor rupture and found that ascites beyond the cul-de-sac was the best indicator of rupture; however, the sensitivity of CT to detect tumor rupture was poor (54 to 70 percent) [<a href="#rid59">59</a>].</p><p>Preoperative imaging helps the surgeon determine whether the tumor is operable at diagnosis. Patients with any of the following findings or circumstances generally undergo an upfront biopsy and receive prenephrectomy chemotherapy rather than initial primary nephrectomy [<a href="#rid60">60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Tumor thrombus above the level of the hepatic veins</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary compromise from massive tumor or extensive pulmonary metastases</p><p class="bulletIndent1"><span class="glyph">●</span>Resection requiring removal of contiguous structures (other than adrenal gland)</p><p class="bulletIndent1"><span class="glyph">●</span>Surgeon judges that attempting nephrectomy would result in significant morbidity, tumor spill, or residual tumor</p><p></p><p class="headingAnchor" id="H2528436941"><span class="h2">Chest imaging</span><span class="headingEndMark"> — </span>Imaging of the chest is needed to determine whether there are lung metastases. At the authors' institution, we routinely perform CT of the chest. If there is a suspicious nodule, a biopsy is performed at diagnosis or after six weeks of therapy to determine whether it represents metastatic disease.</p><p>An alternate approach (used by the International Society of Paediatric Oncology [SIOP]) is to perform the initial evaluation for pulmonary metastases with chest radiography in two planes [<a href="#rid61">61</a>]. A patient with normal chest radiographs is considered to be free of metastatic lung disease. CT is performed in cases of suspicious or positive chest radiography. In addition, chest CT is used to assess the response of the pulmonary nodules to chemotherapy. The management of children with Wilms tumor with lung metastases is discussed separately. (See  <a class="medical medical_review" href="/d/html/6237.html" rel="external">"Treatment and prognosis of Wilms tumor", section on 'Lung metastases'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>Laboratory studies include tests for renal function including urinalysis, liver function, serum calcium, complete blood count, and coagulation studies.</p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine is obtained to detect any reduction in glomerular filtration rate prior to surgical intervention. A urinalysis is sent to detect proteinuria, a finding that can occur in patients with Denys-Drash syndrome and mesangial sclerosis. (See <a class="local">'Denys-Drash syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver function tests may be abnormal with liver metastases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum calcium can be seen in children with rhabdoid tumor of the kidney or congenital mesoblastic nephroma [<a href="#rid62">62</a>]. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coagulation studies, including von Willebrand assay for acquired von Willebrand disease, should be obtained in children who have a history of bleeding or hypervascular tumors because acquired von Willebrand disease occurs in 4 to 8 percent of patients with Wilms tumors at diagnosis [<a href="#rid63">63,64</a>]. Although this abnormality usually has minimal clinical significance [<a href="#rid65">65</a>], there are case reports of severe bleeding requiring intensive intervention [<a href="#rid66">66,67</a>]. As a result, patients with a history of excessive bleeding should be screened for coagulopathy and any abnormality should be corrected perioperatively [<a href="#rid65">65,66</a>]. (See  <a class="medical medical_review" href="/d/html/110531.html" rel="external">"Acquired von Willebrand syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of Wilms tumor includes neuroblastoma and other renal tumors. Imaging studies and tissue histology differentiate Wilms tumor from these other disorders.</p><p>Neuroblastoma can be differentiated from Wilms tumor by contrast-enhanced computed tomography (CT), magnetic resonance imaging (MRI), and/or ultrasonography, which distinguish renal and nonrenal tissue. Final diagnostic confirmation is based upon tissue histology at the time of either biopsy or surgical excision. (See  <a class="medical medical_review" href="/d/html/5187.html" rel="external">"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma", section on 'Diagnostic criteria'</a>.)</p><p>In children, other renal cell tumors are rare [<a href="#rid68">68</a>]. They are differentiated from Wilms tumor by tissue histology:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clear cell sarcoma of the kidney</strong> – Clear cell sarcoma is the second most common pediatric renal tumor. It has a less favorable prognosis than Wilms tumor, with increased rate of relapse and mortality. Bone is a common metastatic site, giving this tumor the alternate name of bone-metastasizing renal tumor of childhood [<a href="#rid69">69</a>]. The histologic appearance is generally distinctive, with cords and nests of pale-stained tumor cells with abundant extracellular matrix separated by a network of fine capillary arcades. However, in some cases, histologic variation can make it difficult to distinguish this tumor from Wilms tumor. As a result, clear cell sarcoma is the most frequently misdiagnosed pediatric renal tumor [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rhabdoid tumor of the kidney</strong> – Rhabdoid tumor of the kidney is a highly malignant renal tumor that occurs most frequently in children less than two years of age and almost never in those older than five years of age [<a href="#rid70">70</a>]. At presentation, the tumor is often metastatic and involving the lungs, abdomen, lymph nodes, liver, bone, and brain [<a href="#rid71">71</a>]. The prognosis is poor, with a reported mortality rate of greater than 80 percent within the first year of diagnosis [<a href="#rid70">70,71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital mesoblastic nephroma</strong> – Congenital mesoblastic nephroma is usually detected within the first year of life or by prenatal ultrasonography and can be divided into the classic and cellular subtypes [<a href="#rid72">72</a>]. It has been associated with hypertension and elevated concentrations of calcium and renin [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal cell carcinoma (RCC)</strong> – RCC is rare in childhood. Children and adolescents with RCC present with more advanced disease than do adults [<a href="#rid74">74,75</a>]. There is a subset of affected adolescent males with a unique chromosomal translocation at Xp11.2, which appears to have a poorer prognosis than non-Xp11.2 translocation RCC [<a href="#rid76">76,77</a>]. In addition, survivors of neuroblastoma who received renal-directed radiation therapy and platinum-based chemotherapy appear to be at risk of developing RCC [<a href="#rid78">78</a>]. Factors associated with increased risk of mortality in children with RCC include advanced disease (ie, stage 4), histologic subtype (ie, non-chromophobe), and nonsurgical treatment as first-line therapy [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/d/html/2982.html" rel="external">"Epidemiology, pathology, and pathogenesis of renal cell carcinoma"</a> and  <a class="medical medical_review" href="/d/html/2983.html" rel="external">"Clinical manifestations, evaluation, and staging of renal cell carcinoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal medullary carcinoma</strong> – Renal medullary carcinoma is a highly lethal tumor that is virtually restricted to patients with sickle cell hemoglobinopathy, most commonly sickle cell trait. It is a highly invasive tumor with early metastases. (See  <a class="medical medical_review" href="/d/html/7199.html" rel="external">"Sickle cell disease effects on the kidney", section on 'Renal medullary carcinoma'</a>.)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">STAGING</span><span class="headingEndMark"> — </span>Staging criteria for Wilms tumor are based upon the anatomic extent of the tumor without consideration for genetic, histologic, or biologic markers [<a href="#rid79">79</a>]. Higher stages represent more extensive disease with a worse prognosis. As a result, more aggressive therapeutic regimens are generally administered to patients with higher tumor stages. (See  <a class="medical medical_review" href="/d/html/6237.html" rel="external">"Treatment and prognosis of Wilms tumor"</a>.)</p><p>There are two major systems currently in use  (<a class="graphic graphic_table graphicRef78599" href="/d/graphic/78599.html" rel="external">table 2</a>) [<a href="#rid79">79</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Children's Oncology Group (COG) – The COG staging system is based upon surgical evaluation <strong>prior</strong> to the administration of chemotherapy. It is used throughout the United States and Canada.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>International Society of Paediatric Oncology (SIOP) – The SIOP system is based upon <strong>post</strong>-chemotherapy surgical evaluation and is used extensively in Europe.</p><p></p><p>Direct comparisons of trials using the two systems are difficult due to the difference in the timing of chemotherapy relative to surgical evaluation [<a href="#rid80">80,81</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Children's Oncology Group system</span><span class="headingEndMark"> — </span>The COG staging system is used throughout the United States and Canada and is based upon surgical evaluation <strong>prior</strong> to the administration of chemotherapy. The first four stages are confined to unilateral involvement:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage I – Tumor is limited to the kidney. The tumor is completely resected with an intact capsule without evidence of renal sinus vessel involvement or tumor at or beyond the margins of resection. There is no previous rupture or biopsy. For a tumor to qualify for certain therapeutic protocols as stage I, regional lymph nodes must be examined microscopically.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage II – Tumor extends beyond the kidney but is completely resected without evidence of tumor at or beyond the margins of resection. Extension includes penetration beyond the renal capsule, invasion of the soft tissue of the renal sinus, or blood vessel involvement beyond the renal parenchyma but within the resected specimen. Rupture of spillage confined to the flank, including biopsy of the tumor, is no longer included in stage II and is now included in stage III.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage III – After surgery, residual tumor remains but is confined to the abdomen. This includes regional lymph node involvement, peritoneal surface involvement, incomplete resection of the tumor, tumor at or beyond the margin of the resection, tumor spillage, previous biopsy, or preoperative chemotherapy before removal of the tumor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage IV – Hematogenous metastasis (eg, lung, liver, bone, brain) or lymph node involvement beyond the abdominopelvic region.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage V – Bilateral renal involvement is present at the time of diagnosis. Each side is then staged separately to guide further management decisions [<a href="#rid79">79</a>].</p><p></p><p class="headingAnchor" id="H18"><span class="h2">International Society of Paediatric Oncology staging</span><span class="headingEndMark"> — </span>SIOP staging is used extensively in Europe and is based upon surgical evaluation <strong>after</strong> administration of chemotherapy to reduce the size of the tumor  (<a class="graphic graphic_table graphicRef78599" href="/d/graphic/78599.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Stage 1 – Tumor is fully resected and is limited to the kidney, or, if outside the kidney, it is surrounded with a fibrous pseudocapsule. Tumor may be found in the renal capsule, pelvic system (but not involving the ureter walls), and intrarenal vessels. There is no evidence of renal sinus vessel involvement or tumor at or beyond the margins of resection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage 2 – Tumor extends beyond the kidney or fibrous pseudocapsule but is completely resected without evidence of tumor at or beyond the margins of resection. Tumor infiltrates, which are completely resected, can extend into the renal sinus, blood vessels and lymph nodes beyond the renal parenchyma, adjacent organs, or vena cava.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage 3 – After surgery, residual tumor remains but is confined to the abdomen. This includes regional lymph node involvement, incomplete resection of the tumor, tumor penetration of the peritoneal surface, tumor thrombi of vessels at resection margins, tumor spillage, or previous biopsy. There is no evidence of hematogenous metastasis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage 4 – Hematogenous metastasis (eg, lung, liver, bone, brain) or lymph node involvement beyond the abdominopelvic region.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage 5 – Bilateral renal involvement is present at the time of diagnosis.</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Wilms tumor is the most common renal malignancy in children and is one of the most common cancers in early childhood  (<a class="graphic graphic_table graphicRef99680" href="/d/graphic/99680.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Almost all cases are diagnosed before 10 years of age and two-thirds before five years of age. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients have solitary Wilms tumor, 5 to 7 percent have bilateral kidney involvement, and 10 percent have multifocal loci within a single kidney. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated congenital syndromes</strong> – Wilms tumor may occur as a part of a multiple malformation syndrome including WAGR syndrome, Denys-Drash syndrome, and Beckwith-Wiedemann syndrome (BWS). (See <a class="local">'Associated congenital syndromes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics </strong>– Wilms tumor is associated with mutations of a number of genes, including the <em>WT1</em>, <em>p53</em>, <em>FWT1</em>, and <em>FWT2</em> genes, as well as mutations at the 11p15.5 loci. (See <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – Tumor histology is linked to patient outcome. The classic favorable histology Wilms tumor is comprised of three cell types (blastemal, stromal, and epithelial cells)  (<a class="graphic graphic_picture graphicRef106078" href="/d/graphic/106078.html" rel="external">picture 1</a>). Anaplasia is associated with poor outcome  (<a class="graphic graphic_picture graphicRef106079" href="/d/graphic/106079.html" rel="external">picture 2</a>). (See <a class="local">'Pathology'</a> above and  <a class="medical medical_review" href="/d/html/6237.html" rel="external">"Treatment and prognosis of Wilms tumor", section on 'Tumor histology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The most common presentation is detection of an abdominal mass or swelling without other signs or symptoms. Symptoms or signs, when present, may include abdominal pain (30 percent of patients), hematuria (12 to 25 percent), and hypertension (25 percent). (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – Screening for Wilms tumor with serial abdominal ultrasonography is performed in high-risk patients (eg, children with BWS or WAGR syndrome). (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – Children who are suspected of having Wilms tumor should be referred to a pediatric cancer center for evaluation and treatment. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The initial imaging study is typically an abdominal ultrasound, which can differentiate Wilms tumor from other causes of abdominal masses. (See <a class="local">'Abdominal imaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) is obtained to evaluate the nature and extent of the mass. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of Wilms tumor is made by histologic confirmation, either at the time of surgical excision or by biopsy. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – Staging of Wilms tumor is based upon the anatomic extent of the tumor without consideration for genetic, histologic, or biologic markers  (<a class="graphic graphic_table graphicRef78599" href="/d/graphic/78599.html" rel="external">table 2</a>). Treatment decisions and evaluation of long-term outcome are based upon the Wilms tumor stage. (See <a class="local">'Staging'</a> above and  <a class="medical medical_review" href="/d/html/6237.html" rel="external">"Treatment and prognosis of Wilms tumor"</a>.)</p><p></p><p class="headingAnchor" id="H1910967309"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jodi A Muscal, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Available at: http://seer.cancer.gov/csr/1975_2012/results_merged/sect_29_childhood_cancer_iccc.pdf (Accessed on December 06, 2015).</li><li class="breakAll">Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (2000-2012) &lt;Katrina/Rita Population Adjustment&gt; - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission. Available at: www.seer.cancer.gov (Accessed on October 06, 2015).</li><li><a class="nounderline abstract_t">Grovas A, Fremgen A, Rauck A, et al. The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer 1997; 80:2321.</a></li><li><a class="nounderline abstract_t">Kalapurakal JA, Dome JS, Perlman EJ, et al. Management of Wilms' tumour: current practice and future goals. Lancet Oncol 2004; 5:37.</a></li><li class="breakAll">Bernstein L, Linet M, Smith MA, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995, SEER Program. Bethesda, MD, National Cancer Institute 1999. p.79.</li><li class="breakAll">Fernandez C, Geller JI, Ehrlich PF, et al. Renal tumors. In: Principles and Practice of Pediatric Oncology, 6th ed, Pizzo P, Poplack D (Eds), Lippincott Williams &amp; Wilkins, St. Louis 2011. p.861.</li><li><a class="nounderline abstract_t">Breslow N, Olshan A, Beckwith JB, Green DM. Epidemiology of Wilms tumor. Med Pediatr Oncol 1993; 21:172.</a></li><li><a class="nounderline abstract_t">Goodman MT, Yoshizawa CN, Kolonel LN. Ethnic patterns of childhood cancer in Hawaii between 1960 and 1984. Cancer 1989; 64:1758.</a></li><li><a class="nounderline abstract_t">Stiller CA, Parkin DM. Geographic and ethnic variations in the incidence of childhood cancer. Br Med Bull 1996; 52:682.</a></li><li><a class="nounderline abstract_t">Fukuzawa R, Breslow NE, Morison IM, et al. Epigenetic differences between Wilms' tumours in white and east-Asian children. Lancet 2004; 363:446.</a></li><li><a class="nounderline abstract_t">Huff V. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 2011; 11:111.</a></li><li><a class="nounderline abstract_t">Scott RH, Stiller CA, Walker L, Rahman N. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet 2006; 43:705.</a></li><li><a class="nounderline abstract_t">MILLER RW, FRAUMENI JF Jr, MANNING MD. ASSOCIATION OF WILMS'S TUMOR WITH ANIRIDIA, HEMIHYPERTROPHY AND OTHER CONGENITAL MALFORMATIONS. N Engl J Med 1964; 270:922.</a></li><li class="breakAll">Dome JS, Huff V, D=GenerReviews: Wilms Tumor Predisposition, available at: http://www.ncbi.nlm.nih.gov/books/NBK1294/ (Accessed on September 21, 2017).</li><li><a class="nounderline abstract_t">Fischbach BV, Trout KL, Lewis J, et al. WAGR syndrome: a clinical review of 54 cases. Pediatrics 2005; 116:984.</a></li><li><a class="nounderline abstract_t">Breslow NE, Norris R, Norkool PA, et al. Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: a report from the National Wilms Tumor Study Group. J Clin Oncol 2003; 21:4579.</a></li><li><a class="nounderline abstract_t">Bliek J, Gicquel C, Maas S, et al. Epigenotyping as a tool for the prediction of tumor risk and tumor type in patients with Beckwith-Wiedemann syndrome (BWS). J Pediatr 2004; 145:796.</a></li><li><a class="nounderline abstract_t">Koufos A, Grundy P, Morgan K, et al. Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am J Hum Genet 1989; 44:711.</a></li><li><a class="nounderline abstract_t">Astuti D, Morris MR, Cooper WN, et al. Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility. Nat Genet 2012; 44:277.</a></li><li><a class="nounderline abstract_t">Hol JA, Kuiper RP, van Dijk F, et al. Prevalence of (Epi)genetic Predisposing Factors in a 5-Year Unselected National Wilms Tumor Cohort: A Comprehensive Clinical and Genomic Characterization. J Clin Oncol 2022; 40:1892.</a></li><li><a class="nounderline abstract_t">Lapunzina P. Risk of tumorigenesis in overgrowth syndromes: a comprehensive review. Am J Med Genet C Semin Med Genet 2005; 137C:53.</a></li><li><a class="nounderline abstract_t">Li M, Shuman C, Fei YL, et al. GPC3 mutation analysis in a spectrum of patients with overgrowth expands the phenotype of Simpson-Golabi-Behmel syndrome. Am J Med Genet 2001; 102:161.</a></li><li><a class="nounderline abstract_t">Neri G, Gurrieri F, Zanni G, Lin A. Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Am J Med Genet 1998; 79:279.</a></li><li><a class="nounderline abstract_t">Hoyme HE, Seaver LH, Jones KL, et al. Isolated hemihyperplasia (hemihypertrophy): report of a prospective multicenter study of the incidence of neoplasia and review. Am J Med Genet 1998; 79:274.</a></li><li><a class="nounderline abstract_t">Byrne J, Nicholson HS. Excess risk for Mullerian duct anomalies in girls with Wilms tumor. Med Pediatr Oncol 2002; 38:258.</a></li><li><a class="nounderline abstract_t">Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatr Pathol 1990; 10:1.</a></li><li><a class="nounderline abstract_t">Beckwith JB. Precursor lesions of Wilms tumor: clinical and biological implications. Med Pediatr Oncol 1993; 21:158.</a></li><li><a class="nounderline abstract_t">Coppes MJ, Haber DA, Grundy PE. Genetic events in the development of Wilms' tumor. N Engl J Med 1994; 331:586.</a></li><li><a class="nounderline abstract_t">Riccardi VM, Sujansky E, Smith AC, Francke U. Chromosomal imbalance in the Aniridia-Wilms' tumor association: 11p interstitial deletion. Pediatrics 1978; 61:604.</a></li><li><a class="nounderline abstract_t">Varanasi R, Bardeesy N, Ghahremani M, et al. Fine structure analysis of the WT1 gene in sporadic Wilms tumors. Proc Natl Acad Sci U S A 1994; 91:3554.</a></li><li><a class="nounderline abstract_t">Shuman C, Smith AC, Steele L, et al. Constitutional UPD for chromosome 11p15 in individuals with isolated hemihyperplasia is associated with high tumor risk and occurs following assisted reproductive technologies. Am J Med Genet A 2006; 140:1497.</a></li><li><a class="nounderline abstract_t">Vuononvirta R, Sebire NJ, Dallosso AR, et al. Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors. Clin Cancer Res 2008; 14:7635.</a></li><li><a class="nounderline abstract_t">Scott RH, Douglas J, Baskcomb L, et al. Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor. Nat Genet 2008; 40:1329.</a></li><li><a class="nounderline abstract_t">Bardeesy N, Falkoff D, Petruzzi MJ, et al. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 1994; 7:91.</a></li><li><a class="nounderline abstract_t">Maschietto M, Williams RD, Chagtai T, et al. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia. PLoS One 2014; 9:e109924.</a></li><li><a class="nounderline abstract_t">Rahman N, Arbour L, Tonin P, et al. Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12-q21. Nat Genet 1996; 13:461.</a></li><li><a class="nounderline abstract_t">Rahman N, Abidi F, Ford D, et al. Confirmation of FWT1 as a Wilms' tumour susceptibility gene and phenotypic characteristics of Wilms' tumour attributable to FWT1. Hum Genet 1998; 103:547.</a></li><li><a class="nounderline abstract_t">McDonald JM, Douglass EC, Fisher R, et al. Linkage of familial Wilms' tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors. Cancer Res 1998; 58:1387.</a></li><li><a class="nounderline abstract_t">Turnbull C, Perdeaux ER, Pernet D, et al. A genome-wide association study identifies susceptibility loci for Wilms tumor. Nat Genet 2012; 44:681.</a></li><li><a class="nounderline abstract_t">Perlman EJ, Gadd S, Arold ST, et al. MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours. Nat Commun 2015; 6:10013.</a></li><li><a class="nounderline abstract_t">Walz AL, Ooms A, Gadd S, et al. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell 2015; 27:286.</a></li><li><a class="nounderline abstract_t">Palculict TB, Ruteshouser EC, Fan Y, et al. Identification of germline DICER1 mutations and loss of heterozygosity in familial Wilms tumour. J Med Genet 2016; 53:385.</a></li><li><a class="nounderline abstract_t">Royer-Pokora B, Weirich A, Schumacher V, et al. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology. Cancer 2008; 113:1080.</a></li><li><a class="nounderline abstract_t">Geller JI. Genetic stratification of Wilms tumor: is WT1 gene analysis ready for prime time? Cancer 2008; 113:893.</a></li><li><a class="nounderline abstract_t">Zuppan CW, Beckwith JB, Luckey DW. Anaplasia in unilateral Wilms' tumor: a report from the National Wilms' Tumor Study Pathology Center. Hum Pathol 1988; 19:1199.</a></li><li><a class="nounderline abstract_t">Ganguly A, Gribble J, Tune B, et al. Renin-secreting Wilms' tumor with severe hypertension. Report of a case and brief review of renin-secreting tumors. Ann Intern Med 1973; 79:835.</a></li><li><a class="nounderline abstract_t">Ritchey ML, Azizkhan RG, Beckwith JB, et al. Neonatal Wilms tumor. J Pediatr Surg 1995; 30:856.</a></li><li><a class="nounderline abstract_t">Suresh I, Suresh S, Arumugam R, et al. Antenatal diagnosis of Wilms tumor. J Ultrasound Med 1997; 16:69.</a></li><li><a class="nounderline abstract_t">Tomá P, Lucigrai G, Dodero P, Lituania M. Prenatal detection of an abdominal mass by MR imaging performed while the fetus is immobilized with pancuronium bromide. AJR Am J Roentgenol 1990; 154:1049.</a></li><li><a class="nounderline abstract_t">Applegate KE, Ghei M, Perez-Atayde AR. Prenatal detection of a Wilms' tumor. Pediatr Radiol 1999; 29:65.</a></li><li><a class="nounderline abstract_t">Vadeyar S, Ramsay M, James D, O'Neill D. Prenatal diagnosis of congenital Wilms' tumor (nephroblastoma) presenting as fetal hydrops. Ultrasound Obstet Gynecol 2000; 16:80.</a></li><li><a class="nounderline abstract_t">Green DM, Breslow NE, Beckwith JB, Norkool P. Screening of children with hemihypertrophy, aniridia, and Beckwith-Wiedemann syndrome in patients with Wilms tumor: a report from the National Wilms Tumor Study. Med Pediatr Oncol 1993; 21:188.</a></li><li><a class="nounderline abstract_t">Scott RH, Walker L, Olsen ØE, et al. Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice. Arch Dis Child 2006; 91:995.</a></li><li><a class="nounderline abstract_t">Tan TY, Amor DJ. Tumour surveillance in Beckwith-Wiedemann syndrome and hemihyperplasia: a critical review of the evidence and suggested guidelines for local practice. J Paediatr Child Health 2006; 42:486.</a></li><li><a class="nounderline abstract_t">Clericuzio CL, Martin RA. Diagnostic criteria and tumor screening for individuals with isolated hemihyperplasia. Genet Med 2009; 11:220.</a></li><li><a class="nounderline abstract_t">Zarate YA, Mena R, Martin LJ, et al. Experience with hemihyperplasia and Beckwith-Wiedemann syndrome surveillance protocol. Am J Med Genet A 2009; 149A:1691.</a></li><li><a class="nounderline abstract_t">Kalish JM, Doros L, Helman LJ, et al. Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma. Clin Cancer Res 2017; 23:e115.</a></li><li><a class="nounderline abstract_t">Servaes S, Khanna G, Naranjo A, et al. Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Children's Oncology Group. Pediatr Radiol 2015; 45:166.</a></li><li><a class="nounderline abstract_t">Khanna G, Naranjo A, Hoffer F, et al. Detection of preoperative wilms tumor rupture with CT: a report from the Children's Oncology Group. Radiology 2013; 266:610.</a></li><li><a class="nounderline abstract_t">Gow KW, Barnhart DC, Hamilton TE, et al. Primary nephrectomy and intraoperative tumor spill: report from the Children's Oncology Group (COG) renal tumors committee. J Pediatr Surg 2013; 48:34.</a></li><li><a class="nounderline abstract_t">Verschuur A, Van Tinteren H, Graf N, et al. Treatment of pulmonary metastases in children with stage IV nephroblastoma with risk-based use of pulmonary radiotherapy. J Clin Oncol 2012; 30:3533.</a></li><li><a class="nounderline abstract_t">Jayabose S, Iqbal K, Newman L, et al. Hypercalcemia in childhood renal tumors. Cancer 1988; 61:788.</a></li><li><a class="nounderline abstract_t">Coppes MJ, Zandvoort SW, Sparling CR, et al. Acquired von Willebrand disease in Wilms' tumor patients. J Clin Oncol 1992; 10:422.</a></li><li><a class="nounderline abstract_t">Fosbury E, Szychot E, Slater O, et al. An 11-year experience of acquired von Willebrand syndrome in children diagnosed with Wilms tumour in a tertiary referral centre. Pediatr Blood Cancer 2017; 64.</a></li><li><a class="nounderline abstract_t">Jonge Poerink-Stockschlader AB, Dekker I, Risseeuw-Appel IM, Hählen K. Acquired Von Willebrand disease in children with a Wilms' tumor. Med Pediatr Oncol 1996; 26:238.</a></li><li><a class="nounderline abstract_t">Leung RS, Liesner R, Brock P. Coagulopathy as a presenting feature of Wilms tumour. Eur J Pediatr 2004; 163:369.</a></li><li><a class="nounderline abstract_t">Baxter PA, Nuchtern JG, Guillerman RP, et al. Acquired von Willebrand syndrome and Wilms tumor: not always benign. Pediatr Blood Cancer 2009; 52:392.</a></li><li><a class="nounderline abstract_t">Isaacs H Jr. Fetal and neonatal renal tumors. J Pediatr Surg 2008; 43:1587.</a></li><li><a class="nounderline abstract_t">Argani P, Perlman EJ, Breslow NE, et al. Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumor Study Group Pathology Center. Am J Surg Pathol 2000; 24:4.</a></li><li><a class="nounderline abstract_t">Palmer NF, Sutow W. Clinical aspects of the rhabdoid tumor of the kidney: a report of the National Wilms' Tumor Study Group. Med Pediatr Oncol 1983; 11:242.</a></li><li><a class="nounderline abstract_t">Vujanić GM, Sandstedt B, Harms D, et al. Rhabdoid tumour of the kidney: a clinicopathological study of 22 patients from the International Society of Paediatric Oncology (SIOP) nephroblastoma file. Histopathology 1996; 28:333.</a></li><li><a class="nounderline abstract_t">van den Heuvel-Eibrink MM, Grundy P, Graf N, et al. Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups. Pediatr Blood Cancer 2008; 50:1130.</a></li><li><a class="nounderline abstract_t">Malone PS, Duffy PG, Ransley PG, et al. Congenital mesoblastic nephroma, renin production, and hypertension. J Pediatr Surg 1989; 24:599.</a></li><li><a class="nounderline abstract_t">Akhavan A, Richards M, Shnorhavorian M, et al. Renal cell carcinoma in children, adolescents and young adults: a National Cancer Database study. J Urol 2015; 193:1336.</a></li><li><a class="nounderline abstract_t">Young EE, Brown CT, Merguerian PA, Akhavan A. Pediatric and adolescent renal cell carcinoma. Urol Oncol 2016; 34:42.</a></li><li><a class="nounderline abstract_t">Tonk V, Wilson KS, Timmons CF, et al. Renal cell carcinoma with translocation (X;1). Further evidence for a cytogenetically defined subtype. Cancer Genet Cytogenet 1995; 81:72.</a></li><li><a class="nounderline abstract_t">Qiu Rao, Bing Guan, Zhou XJ. Xp11.2 Translocation renal cell carcinomas have a poorer prognosis than non-Xp11.2 translocation carcinomas in children and young adults: a meta-analysis. Int J Surg Pathol 2010; 18:458.</a></li><li><a class="nounderline abstract_t">Wilson CL, Ness KK, Neglia JP, et al. Renal carcinoma after childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2013; 105:504.</a></li><li><a class="nounderline abstract_t">Metzger ML, Dome JS. Current therapy for Wilms' tumor. Oncologist 2005; 10:815.</a></li><li><a class="nounderline abstract_t">Perlman EJ. Pediatric renal tumors: practical updates for the pathologist. Pediatr Dev Pathol 2005; 8:320.</a></li><li><a class="nounderline abstract_t">D'Angio GJ. Pre- or post-operative treatment for Wilms tumor? Who, what, when, where, how, why--and which. Med Pediatr Oncol 2003; 41:545.</a></li></ol></div><div id="topicVersionRevision">Topic 6249 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://seer.cancer.gov/csr/1975_2012/results_merged/sect_29_childhood_cancer_iccc.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Available at: http://seer.cancer.gov/csr/1975_2012/results_merged/sect_29_childhood_cancer_iccc.pdf (Accessed on December 06, 2015).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.seer.cancer.gov" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (2000-2012) &lt;Katrina/Rita Population Adjustment&gt; - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission. Available at: www.seer.cancer.gov (Accessed on October 06, 2015).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9404710" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The National Cancer Data Base report on patterns of childhood cancers in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14700607" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Management of Wilms' tumour: current practice and future goals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14700607" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management of Wilms' tumour: current practice and future goals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14700607" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Management of Wilms' tumour: current practice and future goals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7680412" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Epidemiology of Wilms tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2790690" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Ethnic patterns of childhood cancer in Hawaii between 1960 and 1984.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9039726" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Geographic and ethnic variations in the incidence of childhood cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14962525" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epigenetic differences between Wilms' tumours in white and east-Asian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21248786" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16690728" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14114111" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : ASSOCIATION OF WILMS'S TUMOR WITH ANIRIDIA, HEMIHYPERTROPHY AND OTHER CONGENITAL MALFORMATIONS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14114111" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : ASSOCIATION OF WILMS'S TUMOR WITH ANIRIDIA, HEMIHYPERTROPHY AND OTHER CONGENITAL MALFORMATIONS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16199712" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : WAGR syndrome: a clinical review of 54 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14673045" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: a report from the National Wilms Tumor Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15580204" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Epigenotyping as a tool for the prediction of tumor risk and tumor type in patients with Beckwith-Wiedemann syndrome (BWS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2539717" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22306653" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35230882" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prevalence of (Epi)genetic Predisposing Factors in a 5-Year Unselected National Wilms Tumor Cohort: A Comprehensive Clinical and Genomic Characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16010678" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk of tumorigenesis in overgrowth syndromes: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11477610" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : GPC3 mutation analysis in a spectrum of patients with overgrowth expands the phenotype of Simpson-Golabi-Behmel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9781908" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9781907" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Isolated hemihyperplasia (hemihypertrophy): report of a prospective multicenter study of the incidence of neoplasia and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920790" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Excess risk for Mullerian duct anomalies in girls with Wilms tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2156243" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8383276" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Precursor lesions of Wilms tumor: clinical and biological implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8047084" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Genetic events in the development of Wilms' tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/208044" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Chromosomal imbalance in the Aniridia-Wilms' tumor association: 11p interstitial deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8170946" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fine structure analysis of the WT1 gene in sporadic Wilms tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16770802" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Constitutional UPD for chromosome 11p15 in individuals with isolated hemihyperplasia is associated with high tumor risk and occurs following assisted reproductive technologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047088" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18836444" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8075648" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25313908" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8696342" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12-q21.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9860296" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Confirmation of FWT1 as a Wilms' tumour susceptibility gene and phenotypic characteristics of Wilms' tumour attributable to FWT1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9537236" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Linkage of familial Wilms' tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22544364" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A genome-wide association study identifies susceptibility loci for Wilms tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26635203" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25670082" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26566882" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Identification of germline DICER1 mutations and loss of heterozygosity in familial Wilms tumour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18618575" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18618514" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Genetic stratification of Wilms tumor: is WT1 gene analysis ready for prime time?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2844645" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Anaplasia in unilateral Wilms' tumor: a report from the National Wilms' Tumor Study Pathology Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4357546" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Renin-secreting Wilms' tumor with severe hypertension. Report of a case and brief review of renin-secreting tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7666322" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Neonatal Wilms tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8979230" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Antenatal diagnosis of Wilms tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2157328" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prenatal detection of an abdominal mass by MR imaging performed while the fetus is immobilized with pancuronium bromide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084918" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prenatal detection of a Wilms' tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11084972" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prenatal diagnosis of congenital Wilms' tumor (nephroblastoma) presenting as fetal hydrops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8095320" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Screening of children with hemihypertrophy, aniridia, and Beckwith-Wiedemann syndrome in patients with Wilms tumor: a report from the National Wilms Tumor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16857697" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16925531" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Tumour surveillance in Beckwith-Wiedemann syndrome and hemihyperplasia: a critical review of the evidence and suggested guidelines for local practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19367194" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Diagnostic criteria and tumor screening for individuals with isolated hemihyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19610116" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Experience with hemihyperplasia and Beckwith-Wiedemann syndrome surveillance protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28674120" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25135711" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23192775" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Detection of preoperative wilms tumor rupture with CT: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23331790" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Primary nephrectomy and intraoperative tumor spill: report from the Children's Oncology Group (COG) renal tumors committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22927531" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Treatment of pulmonary metastases in children with stage IV nephroblastoma with risk-based use of pulmonary radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2827881" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Hypercalcemia in childhood renal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1311024" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Acquired von Willebrand disease in Wilms' tumor patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27616321" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : An 11-year experience of acquired von Willebrand syndrome in children diagnosed with Wilms tumour in a tertiary referral centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8600334" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Acquired Von Willebrand disease in children with a Wilms' tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15071738" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Coagulopathy as a presenting feature of Wilms tumour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19006222" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Acquired von Willebrand syndrome and Wilms tumor: not always benign.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18778991" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Fetal and neonatal renal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10632483" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumor Study Group Pathology Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6310357" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Clinical aspects of the rhabdoid tumor of the kidney: a report of the National Wilms' Tumor Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8732342" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Rhabdoid tumour of the kidney: a clinicopathological study of 22 patients from the International Society of Paediatric Oncology (SIOP) nephroblastoma file.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18095319" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2544716" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Congenital mesoblastic nephroma, renin production, and hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25451825" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Renal cell carcinoma in children, adolescents and young adults: a National Cancer Database study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26299882" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pediatric and adolescent renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7773963" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Renal cell carcinoma with translocation (X;1). Further evidence for a cytogenetically defined subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20643670" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Xp11.2 Translocation renal cell carcinomas have a poorer prognosis than non-Xp11.2 translocation carcinomas in children and young adults: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23515901" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Renal carcinoma after childhood cancer: a report from the childhood cancer survivor study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16314292" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Current therapy for Wilms' tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16010493" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pediatric renal tumors: practical updates for the pathologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14595712" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pre- or post-operative treatment for Wilms tumor? Who, what, when, where, how, why--and which.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
